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ADAPTING TO STRESS: UNDERSTANDING THE NEUROBIOLOGY OF RESILIENCE 
 
 
ABSTRACT 
 There is significant variation in the way individuals react and respond to extreme stress and 
adversity. While some individuals develop psychiatric conditions such as Post-Traumatic Stress 
Disorder (PTSD) or Major Depressive Disorder (MDD), others, recover from stressful experiences 
without displaying significant symptoms of psychological ill-health, demonstrating stress-resilience. To 
understand why some individuals exhibit characteristics of a resilient profile, the interplay between 
neurochemical, genetic and epigenetic processes over time needs to be explained. In this review, we 
examine the hormones, neuropeptides, neurotransmitters and neural circuits associated with resilience 
and vulnerability to stress-related disorders. We debate how this increasing body of knowledge could 
also be useful in the creation of a stress-resilient profile. Additionally, identification of the underlying 
neurobiological components related to resilience may offer a contribution to improved approaches 
toward the prevention and treatment of stress-related disorders.      
 
INTRODUCTION 
Stress can be defined as a physiological and psychological reaction of the body toward an event 
or situation, commonly termed a stressor. The given stressor can be perceived broadly as either 
challenging or threatening1-3. Challenges that are perceived as exhilarating, while at the same time 
being manageable, are normally classified as positive and beneficial to the individual, leading to 
accomplishment. However, threatening experiences, which are perceived as irritating or imposing 
significant danger, may result in short-term or long-term physiological and psychological ill health4,5. 
 The brain is the central organ responsible for the stress response. It processes perceptual 
information for potential threats and initiates a response. Secondly, it regulates the physiological and/or 
psychological responses that can either be adaptive or damaging to the individual4. Furthermore, the 
brain is responsible for establishing a two-way communication between itself and the immune and 
cardiovascular systems via endocrine and neural mechanisms during the stress response4,6.   
 The adaptive physiological response to acute stress comprises a process known as allostasis. 
This process performs the function of maintaining the internal viability of the organism amid changing 
environmental conditions7-9. In the short term, this is achieved by physiological changes in the 
Autonomic Nervous System (ANS) through the Sympathetic Nervous System (SNS), Hypothalamic-
Pituitary-Adrenal (HPA) Axis hormones, cytokines and a number of other systems10,11.   
A physiological response to environmental stressors is of evolutionary advantage as a function 
of the acute stress response, more commonly known as the “fight-or-flight” mechanism12. However, if 
recovery is not accompanied by an adequate homeostatic response, the initial response could ultimately 
2 
result in harmful after effects13. The prevailing effects of stress have been conceptualised as the 
allostatic load, which represents the physiological and psychological consequences of repeated chronic 
exposure to heightened neuroendocrine responses. In turn, the cumulative effect of these responses can 
result in psychopathological conditions such as Post-Traumatic Stress Disorder (PTSD) and Major 
Depressive Disorder (MDD), among others14,15.  
 By examining how humans and animals adapt to highly aversive environments, researchers 
have recently identified some of the neural, neurochemical, genetic and epigenetic components that 
may characterize vulnerability, and conversely resilience, in individual responses16-18. This paper 
assesses the role of these factors in relation to individuals who appear to show resilience in the face of 
extreme or repeated traumatic stressors. This review had three main objectives. First, understand the 
dynamic concept of stress and resilience and what differentiates a resilient from a non-resilient 
individual; second, identify the neurochemicals, genetic and epigenetic mechanisms hypothesised as a 
basis of resilience or vulnerability to a stress-related disorder; third, to understand whether the ability to 
cope with high levels of stress are inborn, inherited and/or acquired through specific training (e.g. 
through a stress inoculation process) or some combination of the above. A comprehensive review of the 
current research and introduction to the physical processes associated with resilience is of interest and 
importance to the medical community.  
 The literature search was conducted between February 2014 and June 2014. Relevant studies 
published in peer-reviewed journals were identified through electronic searches on PubMed, Web of 
Science, Embase, PsycINFO databases. Key search terms to identify title and/or abstract included 
words such as: “stress” OR “resilience” OR “adaptation” OR “allostasis” OR “allostatic load” OR 
“PTSD” OR “depression” combined with “physiology” OR “psychopathology” OR “neurochemistry” 
OR “neuropeptide” OR “neurotransmitters” OR “hormones” OR “neurobiological factors” OR 
“endocrine system” OR “sympathetic nervous system” OR “hypothalamic-pituitary-adrenal axis” OR 
“central nervous system” OR “genes” OR “genetic” OR “genetic variation” OR “epigenetic” OR 
“psychiatric disorders” OR “toxic”.  
 
UNDERSTANDING RESILIENCE TO STRESS           
Concept of Resilience 
 Resilience is the dynamic process through which an individual can adaptively overcome a 
stressful and/or traumatic event(s), while maintaining relatively normal physical and psychological 
function over time19-21. Additionally, resilience is referred to as a two-dimensional construct. This 
implies that when an individual has been subject to a stressor (such as exposure to a life-threatening 
event), the experience has led to a positive adjustment. As such, this bi-dimensional construct implies 
two evaluations. The first is about the significance of risk or adversity associated with negative life 
conditions, and the second is about how a positive “adaptation” is displayed through behaviour on 
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social competence or success at that specific life stage22. In this context, individuals classified as stress 
resilient are normally defined as exhibiting an enhanced capacity of avoiding deleterious physiological 
and psychological consequences as a result of exposure to extreme stress, which could otherwise result 
in serious stress-related psychiatric disorders, such as PTSD or MDD16,20. It is important to mention 
that resilience is not conceptualised as the absence of a diagnosable psychiatric condition but rather a 
constructive adaptation to adversity and traumatic experience19,22.  
The characterization of resilience is still difficult to conceptualise and operationalize, as it 
represents many forms of successful adaptive biological, behavioural and cognitive responses to 
traumatic events21,23. As individuals exhibit a pattern of recuperation from life-threatening experiences, 
researchers have sometimes used the concept of resilience inappropriately. For example, other adaptive 
responses to traumatic experiences such as recovery from trauma can also be observed. The concept of 
recovery from trauma, indicates a trajectory in which normal functioning temporarily gives way to a 
disruption through the manifestation of significant psychiatric symptoms for a period of several 
months, followed by a slow but yet significant recovery over months to levels of functioning prior to 
trauma19,24. Therefore, while both these responses are similar in the long-term, only the resilient ones 
exhibit a stable trajectory of healthy functioning over time19,24. In this review, we will only characterize 
the biological stress responses known to be linked with resilient phenotypes and how their enhanced 
neurobiological response is processed. 
 
NEUROCHEMICAL, GENETIC, EPIGENETIC FACTORS IN STRESS RESILIENCE 
Neurochemical Factors in Stress Resilience 
A significant number of neurochemicals (such as neuropeptides, hormones and 
neurotransmitters) are involved in the acute psychobiological response to stress. These neurochemicals 
have been investigated in relation to stress resilience, and conversely, to the risk of 
psychopathology10,16. According to several studies, these neurochemicals have been shown to be 
significantly altered by stress and to perform an important functional interaction in the brain, by 
mediating the neural circuits and molecular pathways relevant to cognitive functioning, fear 
conditioning, regulation of reward and social behaviour10,17. So far, some of the neurochemical 
components linked to stress resilience include constituents of the SNS, for example norepinephrine 
(NE) and neuropeptide-Y (NPY) or galanin, from the HPA Axis, corticotropin-releasing hormone 
(CRH), cortisol, dehydroepiandrosterone (DHEA), and from other systems including the dopaminergic, 
serotonergic systems, brain-derived neurotropic factor (BDNF), or neurosteroidogenic enzymes10,18,25. 
 
- Sympathetic Nervous System (SNS) 
Under circumstances of potential danger, the human and animal SNS will release 
neurochemical components such as epinephrine, the hormone responsible for the fight-or-flight 
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response, and NE in order to protect the organism from the perceived threat. However, danger response 
varies from one individual to the other, and therefore stress responses can vary significantly12,26. 
 In cases where individuals exhibit an unusual hyper-sensitive SNS response to stress, they can 
be subject to a higher risk of chronic anxiety, intrusive memories, fear, hypervigilance, and in some 
cases be diagnosed as having PTSD27. It is also recognised that the maintenance of an SNS response 
within a certain level of activation, not so high to result in psychiatric symptoms though, has been 
observed in highly resilient individual28,29. 
 
- Norepinephrine (NE) 
 NE is a catecholamine present within cells of the Central (CNS) and Peripheral Nervous System 
(PNS) and is known to work as a neurotransmitter during the stress response27. NE is particularly noted 
for its function in cognitive alertness and vigilant concentration in individuals under stress27. Under 
stressful circumstances, the organism will release NE from the brainstem nuclei and locus coeruleus. In 
turn NE modulates the fight-or-flight response along with epinephrine by immediately increasing its 
heart rate, pressing the liberation of glucose from energy stores and so increasing blood stream to 
skeletal muscle and brain oxygen supply30. A higher activation of the NE system is known for 
inhibiting functions in the prefrontal cortex, and therefore promoting instinctual responses over more 
complex cognitive responses30. 
 Clinical evidence suggests that abnormal regulation of brain NE systems is observed in patients 
with PTSD, through symptoms such as re-experiencing, hyperarousal, tachycardia, increased diastolic 
blood pressure, and diaphoresis27. However, studies that evaluated the blockade of β-adrenergic 
receptors in the amygdala were thought to ameliorate the development of aversive memories in human 
and animal studies13,31. Thus, based on these findings, some authors suggest that a reduced 
responsiveness of NE could be linked with resilience to stress17.   
 
- Neuropeptide-Y (NPY) 
 NPY is a 36-amino acid neuropeptide highly expressed in the mammalian brain and known to 
act as a neurotransmitter. It is produced in several areas of the brain, such as the hypothalamus, and is 
believed to have several important functions, including reducing anxiety, stress, pain perception, 
circadian rhythms and lowering blood pressure27,32. Normally, NPY is released with NE when the SNS 
is highly activated. One of its main functions, is to restrain the ongoing release of NE and to prevent 
SNS overshoots27,32. Numerous studies have proved the valuable function of NPY in mediating 
resilience and vulnerability to stress in both animals and humans29,32-34. For example, studies with small 
rodents presenting PTSD-like behaviour exhibit a significant down-regulation of NPY in various areas 
of the brain, particularly the hippocampus and amygdala. Additionally, centrally administered NPY 
doses in these small rodents showed a reverse in these negative behaviours (such as lower predator-
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scent stress)35. Studies conducted on military personnel participating in particularly stressful training, 
known as Survival, Evasion, Resistance and Escape (SERE), compared highly resilient members of the 
US Special Forces with their regular infantry counterparts. The Special Forces participants were shown 
to produce higher concentrations of NPY and exhibit an enhanced physical and psychological 
performance, followed by a reduced vulnerability to stress-induced anxiety and dissociation. These 
robust increases of NE in the US Special Forces personnel were followed by similar robust increases in 
the levels of NPY29,34.  
 In support, of the importance of NPY as a mediating factor in the stress response, one study 
compared a healthy civilian control group to a group of military veterans diagnosed as having PTSD. 
The study comprised a rest stage and a stress stage, the findings revealed that the veteran group 
displayed lower levels of NPY in each phase36. Studies of veterans who suffered from PTSD showed 
that they exhibited a significant increase in NE levels which was not positively accompanied by a 
significant increase in their NPY levels. It is hypothesised that this maintained symptoms of anxiety, 
hyper-vigilance and intrusive combat-related memories27,36. Additionally, other clinical studies have 
also shown that decreased concentrations of NPY in plasma and cerebrospinal fluid (CFS) were 
observed in individuals with PTSD and MDD37,38. 
In view of the current evidence, NPY can be seen as a novel molecular therapeutic target aimed 
to ameliorate and/or treat symptoms of PTSD. Indeed, a recent study examining the properties of 
intranasal NPY in a single prolonged stress animal model of PTSD showed reducing anxiety-like 
behaviours, particularly when administered before the stress task39. In term of human studies, we are 
only aware of one approved by the US National Institutes of Health (NIH) to investigate the safety and 
efficacy of intranasal NPY administration to individuals suffering from PTSD. At the time of writing 
this review the study was in the recruitment phase and as such results were not available for inclusion40. 
 
- Galanin    
 Galanin is a 30-amino acid neuropeptide existent in humans and encoded by the GAL gene, 
which is extensively expressed in the brain, and is known to have a significant effect in the SNS 
response. While the functional role of galanin is still vastly unknown, this neuropeptide appears to have 
some neuroprotective activity in the PNS and in the promotion of neurogenesis41,42. Galanin is known 
to have an effect on the cardiovascular and sleep regulation, anxiety response, learning skills, memory 
and pain response control43. Further to this, galanin is also known to be an inhibitory hyperpolarizing 
neuropeptide, alike NPY44. 
A significant high percentage, approximately 80%, of noradrenergic neurons located in the 
locus coeruleus (situated in the nucleus of the pons) are involved in the physiological response to stress 
and panic and co-express galanin10,45. Galanin is normally released when NE is highly activated. 
Consequently, its activity reduces the firing action of the locus coeruleus45,46. In rodent behavioural 
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studies, centrally administered galanin has been known to modulate anxiety-like behaviours and when 
injected directly into the central nucleus of the amygdala, it was shown to block the negative effects of 
stress47,48. These findings suggest that the noradrenergic response to stress leads to the release of 
galanin into the central nucleus of the amygdala as a protection against the anxiogenic effects of NE10. 
Conversely, researchers that studied knockout mice galanin receptors found that these animals showed 
increased anxiety-like behaviour, leading to an augmented vulnerability to anxiety and isolation11. 
According to these findings, the response to stress noradrenergic response may be contingent on a 
balance established between NE, NPY and galanin transmission10.  
Novel approaches to evaluate the enhanced therapeutic characteristics of galanin are currently 
underway. For example, a study which evaluated small rodents exposed to different sets of experiences 
and stress tasks, revealed that both physical exercise and galanin therapy rodent groups exhibit 
decreased anxiety-like behaviours, while the group of rodents deprived of exercise exhibit increased 
anxiety-like behaviours. According to the authors, both physical exercise and galanin therapy groups 
demonstrated increased levels of galanin49.  
  
- Hypothalamic-Pituitary-Adrenal (HPA) Axis 
A complex set of brain interactions between the hypothalamus, the pituitary gland and the 
adrenal gland, known as HPA Axis, play a crucial role in the human and animal stress response25,50-52. 
Under an immediate threatening or stressful event, the hypothalamus releases a peptide hormone and 
neurotransmitter known as CRH into the hypothalamic-hypophyseal portal system (the connection 
between the hypothalamus and anterior pituitary) to mediate its stress response. The hypothalamic-
hypophyseal portal system will then carry out the CRH into the anterior lobe of the pituitary where it 
will stimulate the production of another polypeptide tropic hormone known as adrenocorticotropic 
hormone (ACTH). In turn, the ACTH hormone stimulates the synthesis of two steroid hormones, 
cortisol and DHEA into their stress response52.  
 In several human and animal studies, resilience has been associated with the brain’s ability to 
moderate stress-induced increases in CRH and cortisol. This operation occurs through an elaborate 
negative feedback system which involves an optimal functioning and equilibrium of mineralocorticoid 
and glucocorticoid receptors53,54. 
 
- Corticotropin-Releasing Hormone (CRH)  
 CRH is a 41-amino acid peptide hormone and neurotransmitter encoded by the CRH gene and 
is known to play an important role in the acute stress response. Particularly in increased arousal, motor 
activity and reduced reward expectations and activated fear behaviours55. CRH acts via the two 
receptors (CRH-1 and CRH-2), which are normally secreted by the paraventricular nucleus (PVN) of 
the hypothalamus in response to stress56. Studies that evaluated different concentration levels found 
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that increased CRH concentrations have been associated with PTSD, MDD and symptoms of fear and 
anxiety57-59. Conversely, those individuals who displayed reduced CRH concentrations were normally 
found be to resilient individuals10.  
CRH-1 and CRH-2 receptors are spread in the different areas of the brain. CRH-1 receptor is 
normally found in the hippocampus, basolateral amygdala and neocortex, while CRH-2 receptor is 
normally found in the dorsal raphe, medial and cortical nuclei of the amygdala and lateral septum60. 
The CRH-1 signaling is known to play a role in the anxiogenic circuit and leads to anxiety-like 
responses, while the CRH-2 controls the effects of CRH-1 signaling, and can either be anxiogenic or 
anxiolytic61-63. In rodent studies where they exhibited a deficiency in the CRH-1 receptor, the animals 
displayed a reduced anxiety-like behaviour and a diminished stress response. However, animals that 
exhibited a deficiency in the CRH-2 receptor showed augmented anxiety like-behaviours and were 
hypersensitive to stress64-66. According to these findings, the triggering of the CRH-1 receptors are 
potentially linked with anxiety-like responses, while the triggering of the CRH-2 receptors are 
potentially linked with anxiolytic-like responses. Though evidence exists highlighting the properties of 
CRH in animals, until now it has not been possible to examine the CRH-1 and CRH-2 receptors in 
humans10.  
 
- Cortisol 
Cortisol is a glucocorticoid that is part of the class of the steroid hormones produced by the 
zona fasciculata of the adrenal cortex. Its primary function is to mobilize and replenish energy stores67. 
Cortisol is also known to perform an important role in the stress response by way of significant 
increases in vigilance, increased arousal, consolidation of memory and selective attention68. While 
cortisol has an important regulatory effect on the amygdala, hippocampus and prefrontal cortex, the 
prolonged exposure to high levels of cortisol in the organism proved to have significant toxic effects, 
particularly in the neurodegeneration of the hippocampus, resulting in memory and learning deficits67. 
Studies that included cortisol supplementation in healthy individuals revealed that the repeated 
administration of cortisol led to significant cognitive impairments, similar to those observed in patients 
diagnosed with depression69. It is also well documented that excessively low and high cortisol levels 
have been found in individuals with a PTSD diagnosis70. Recent findings suggest that in order to 
modulate the negative effects of cortisol, DHEA (which is also secreted with cortisol) serves a 
protective role, and is associated with resilience16. 
  
 - Dehydroepiandrosterone (DHEA) and DHEA Sulfate Ester (DHEA-S) 
 DHEA and DHEA-S are two endogenous hormones secreted by the adrenal cortex, and are 
known to be the most abundant circulating steroid hormones present in humans71-73. While their precise 
mechanisms of action are not completely understood, some studies suggest that DHEA and its 
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derivative sulfate ester might serve in a variety of physiological aspects in the organism. These include 
control of fatness, mineral metabolism, sexual functioning, anti-inflammatory and antioxidant effects71-
73. Further studies also hypothesize that DHEA may exert a protective response against stress71,72. 
 Several military studies highlighted the beneficial properties of DHEA and DHEA-S in 
supporting a protective role. A number of studies were conducted on healthy military personnel 
undergoing the SERE training school or the Combat Diver Qualification Course (CDQC). The results 
showed that soldiers who performed better under acute stress had a higher increased of DHEA or 
higher DHEA-to-cortisol ratio in the blood. These soldiers also showed a superior physical and 
psychological performance and reported fewer symptoms of dissociation71-73. A further innovative 
study provided endogenous DHEA supplementation in a randomized, controlled, double-blind field 
study. They used a treatment versus control group, within a group of soldiers undergoing SERE 
training. The study focused on higher salivary concentrations of DHEA and DHEA-S as a result of 
DHEA treatment, none of the group differences resulted in a superior performance or in a reduction of 
dissociative symptoms74. In general, DHEA administration studies with humans have failed to show 
any evidence of improved neurocognitive performance on their outcomes75,76. However, there has been 
a double blind, placebo-controlled trial study which found improved mood and memory recollections 
after DHEA treatment in a sample of healthy young men. Though, individuals in this latest study were 
not exposed to any form of stress task77.   
 Nevertheless, studies evaluating these two steroid hormones reported that a reduced 
concentration of DHEA ratio-to-cortisol can be translated into a higher risk of experiencing chronic 
fatigue syndrome, anxiety, anorexia nervosa, depression, schizophrenia and PTSD71. Yet, this pattern 
of findings has not been observed thoroughly in all PTSD studies, which in relation to each other show 
conflicting results78,79.  
 
 - Dopaminergic System, Dopamine 
 Dopamine is a hormone and neurotransmitter implicated in various neural functions including 
attention, motivational behaviour and motor control. Dopamine is also known to play an important role 
in the stress response80. Stress inhibits the release of dopamine in the nucleus accumbens, an area 
mainly associated with the reward pathway, and activates the release of dopamine in the medial 
prefrontal cortex, an area associated in complex cognitive behaviour, personality expression, decision 
making and moderating social behaviour10. A further study evaluated lesions of dopamine neurons in 
the medial prefrontal cortex, the results suggested that reduced prefrontal cortical dopamine levels lead 
to the maintenance of the fear response, an outcome normally observed in individuals with PTSD81. 
Conversely, studies that identified high levels of dopamine release in the medial prefrontal cortex 
resulted in cognitive impairment. Thus, the data suggests that there is an optimal range for stress-
induced increases in dopamine, released in the medial prefrontal cortex, that may facilitate 
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advantageous behavioural responses. There has, until now, been little research concerning the function 
of dopamine in stress-related disorders10. 
 
 - Serotonergic System, Serotonin 
 Serotonin is a monoamine neurotransmitter present in the Central Nervous System (CNS). It is 
known to have an effect on the regulation of appetite, sleep, feelings of wellbeing and happiness. 
Serotonin is also known for its effects on mood and anxiety. The acute stress response is linked with 
the augmented serotonin turnover in different areas of the brain, particularly in the lateral 
hypothalamus, amygdala, prefrontal cortex and nucleus accumbens18,30,82. The liberation of serotonin in 
the brain is known to have both anxiolytic and anxiogenic effects, and this outcome is mediated by 
which part of the forebrain and receptors are stimulated. For example, stimulation of the serotonin 2A 
receptor results in anxiogenic effects, while the stimulation of the serotonin 1A are anxiolytic and 
potentially associated with adaptive reactions to stressful occurrences83,84. Two additional serotonin 
receptors, particularly the serotonin 1B and 2C receptors, have also been studied and though to be 
associated with adaptive reactions to stressful circumstances30. 
 
- Brain-Derived Neurotropic Factor (BDNF) 
 BDNF is a protein encoded by the BDNF gene and is part of the neurotrophin family of growth 
factors85,86. This neurotropic factor works in specific neurons of the CNS and PNS, and is known for 
supporting the survival of existing neurons, by stimulating the growth and differentiation of new 
neurons and synapses87,88. BDNF is expressed in several regions of the brain such as the amygdala, 
prefrontal cortex, hippocampus and basal forebrain, and is implied in anxiety and mood disorders18. 
 Numerous studies have reported that a down-regulation of BDNF in the hippocampus has been 
observed in small rodents exposed to various types of stressors and in depressed patients who 
successfully committed suicide89,90. According to some authors, hippocampal BDNF expression may 
have a significant influence in both stress resilience and risk of psychiatric problems18. BDNF acts 
through the BDNF-tyrosine kinase B (BDNF-TrkB) receptor. According to some human and animal 
studies that evaluated the BDNF-TrkB pathway, this receptor was related with PTSD 
symptomatology91. Conversely, those studies which administered antidepressants found an increase in 
BDNF-TrkB receptors in the hippocampus and prefrontal cortex and a potential role to hippocampal 
neurogenesis92. However, this evidence was not observed in all BDNF-TrkB studies18.  
 
- Neurosteroidogenic Enzymes, Allopregnanolone (ALLO) 
ALLO is a cholesterol-derived neuroactive steroid present in the CNS that is synthesized from 
progesterone, a steroid hormone, in a two-step pathway, by action of the 5α-reductase and 3α-
hydroxysteroid dehydrogenase enzymes, both steroidogenic enzymes93,94. In particular, certain 3α-
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reduced metabolites of progesterone such as ALLO are potent positive allosteric modulators of the 
Gama-Aminobutyric Acid (GABAA) receptor, particularly known for being the chief inhibitory 
neurotransmitter in the vertebrate CNS93,94.  
Stress increases ALLO levels in the brain to concentrations that can activate the GABAA 
receptors, and according to several studies ALLO might have potential pharmacological properties, 
particularly anticonvulsant and anxiolytic actions94,95. New hypothesis concerning the putative 
anxiolytic and antidepressant properties of ALLO involve the role of stress in the HPA Axis 
dysregulation95,96. Acute stress produces an increase in ALLO levels which negatively modulates the 
stress-induced HPA Axis activation, thus aiding the recovery of physiological homeostasis after a 
stressful stimuli97,98. For example, in a study of small rodents, forced-swimming stress induced a time-
dependent increase in the amount of ALLO and progesterone, both in the plasma and in brain areas 
such as cerebral cortex, hypothalamus and plasma by producing protection against the damaging effects 
of stressors97. Nevertheless, other studies investigating chronic stress response, highlight a significant 
reduction in the ALLO concentration levels. This suggests that chronic stress may alter ALLO 
synthesis and lead to a dysregulation in the HPA Axis98. In a recent study of small rodents, chronic 
stress was associated with a significant reduction in endogenous ALLO levels and an increased risk of 
anxiety-like behaviours and depression98. The exogenous administration of ALLO from the onset of 
isolation-induced chronic stress and a period of chronic stress was able to reduce the occurrence of 
anxiety-like behaviours and depression, and regulate the HPA Axis dysfunction95. Based on these 
findings, it appears that ALLO is a key regulator of physiological functions and potentially important 
variable in resilience.  
 
Early Genetic Factors in Stress Resilience 
 Genetics is the process of trait inheritance through the sharing of molecular structure and 
function of genes, gene behaviour and distribution, variation and change among similar or related 
organisms99. Genetic factors play a very significant function in the determination of an individual’s 
response to stress and therefore regulate their risk or resilience to a psychiatric condition17,18. Indeed, 
studies developed with identical twins have projected an overall heritability rate of 32% to 38% in 
PTSD cases100. Some studies considering individuals Deoxyribonucleic Acid (DNA) genetic make-up 
and their particular history of exposure to environmental stressors found that stress regulation response 
could be significantly affected by genetically modified differences in reactivity of the SNS, of the CNS 
through the HPA Axis, the noradrenergic and dopaminergic system, the serotonergic system, and the 
BDNF17,18,100. We should mention here that this area is still largely unexplained and particularly 
unknown101. 
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- Sympathetic Nervous System (SNS) Related Genes 
Regulation of the SNS can also be affected by genetic factors. Demonstrating the fundamental 
role of SNS reactivity, is a study that evaluated the genetically modified variation of SNS activity in a 
group of healthy individuals, found that a polymorphism in the alpha adrenergic-2 receptor gene 
appears to be considerably linked with their autonomic hyper-responsiveness102. Further, another study 
found that during stress exposure, NPY levels were disturbed by polymorphism in the gene encoding of 
the NPY molecule103. This suggests that the association between the noradrenergic system (NE) and 
stressor might be mediated by different alpha-2 adrenergic receptors subtypes. Consequently, when 
researchers evaluated the effects of mice knocked out by the alpha-2A adrenergic receptor, their 
findings suggested this receptor displayed stress-protective functions. Opposing these findings other 
studies have shown the alpha-2C adrenergic receptor was involved in stress susceptibility101,104.   
The SNS response to stress may also be disturbed by changes in the NPY-gene17,18. Supporting 
this evidence, a study found that two NPY haplotypes have been associated with increased 
vulnerability to anxiety symptoms after experiencing severe adversity during youth105. Another study 
evaluated the effects of NPY genetic expression on emotions and stress resilience and revealed that the 
presence of lower haplotype-driven NPY expression was predictive of diminished resilience, assessed 
by the presence of a higher emotional-induced activation of the amygdala in the brain106. Still, the long 
term variant of the NPY encoding gene was related to a reduced PTSD susceptibility and negative 
emotional states in depression106,107.     
 
 - Hypothalamic-Pituitary-Adrenal (HPA) Axis-Related Genes  
 Changes in genes that control HPA Axis reactivity appear to contribute significantly to 
modifications in biologically-based stress response systems and influence resilience or vulnerability to 
psychiatric conditions100,108. Polymorphisms (mutation in the genotype) and haplotypes (combination 
of DNA sequences) in two key genes of the HPA Axis include the corticotropin-releasing-hormone 
receptor 1 gene (CRHR1 gene) and the FK506-binding protein 5 gene (FKBP5), both potentially 
known for interacting with early life trauma (childhood maltreatment or abuse) and predictive of later 
life stress-related psychiatric conditions108. A significant number of studies have examined CRHR1 
gene variation in PTSD and MDD in individuals exposed to life-threatening circumstances. For 
example, the genetic marker spanning the CRHR1 receptor gene rs110402 has been associated with 
cortisol levels and the developing of depression in adult males who experienced trauma during their 
childhood109. Other studies found protective effects of the CRHR1 TAT haplotype rs7209436, 
rs110402, rs242924 genetic markers in adults who have been victims of childhood maltreatment110. 
Concerning the FKBP5 gene, studies have shown the involvement of this gene in the modulation of the 
glucocorticoid receptor activity and signaling, and predicted the severity of the onset of depression and 
PTSD symptoms in adult with childhood trauma111,112.  
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- Noradrenergic and Dopaminergic Genes System  
Another polymorphism that has been associated with vulnerability to a psychiatric condition is 
found in the gene that codes Catechol-O-Methyltransferase (COMT), an enzyme degraded in the 
noradrenergic and dopaminergic systems113. The COMT Val158Met polymorphism has been studied in 
relation to stress and psychiatric disorders, suggesting an association with cases of PTSD113. For 
example, in a human study evaluating traumatic load, diagnosis of PTSD and COMT Val158Met 
polymorphism, results showed that a gene environment interaction among the human COMT Val158 
Met polymorphism and the magnitude of traumatic events experienced increased the risk of developing 
PTSD114. Another study was developed with a sample of Vietnam and Gulf War veterans who 
experienced significant amounts of operational stress. Its findings also suggested that COMT 
Val158Met polymorphism moderated the effect of PTSD-related processes on right anterior cingulate 
cortex volume115. 
Polymorphisms in the dopaminergic receptor genes have also been associated in the risk of 
developing depression and PTSD. According to a study that evaluated the Dopamine Transporter gene 
polymorphism (DAT1), the results suggest that this gene contributed significantly to a susceptibility to 
PTSD in those individuals with a previous history of trauma116. Additionally, studies that evaluated the 
Dopamine receptor gene D2 polymorphism (DRD2) suggest that determined DRD2 signaling 
explained part of personality traits related to emotion processing as well as individuals variability in 
specific brain responses to emotionally relevant inputs117. Another study that evaluated the Dopamine 
receptor gene D4 polymorphism (DRD4) showed that this polymorphism influenced vulnerability to 
stress and trauma and a significant higher risk of developing a case of PTSD118. 
 
 - Serotonergic Gene System 
 Several studies assessing the polymorphic trait characteristics of the serotonin transporter gene, 
through the effects of gene multiplied by environment interactions, have promoted advances in the area 
of stress-related disorders18. For example, in studies that evaluated the interaction between stress and 
the polymorphism in the promoter region of the serotonin transporter gene (5-HTTLPR), results 
showed the presence of the shorter allele of 5-HTTLPR linked with an increased risk for depression 
and PTSD119,120. Conversely, human studies evaluating the presence of the long allele of the 5-
HTTLPR found a positive association with self-reported emotional resilience121.   
 
 - Brain-Derived Neurotropic Factor (BDNF) Genes 
 Recent scientific evidence suggests that BDNF Val66Met polymorphism may be potentially 
linked with the modulation of the stress reactivity in humans122,123. For example, a study that evaluated 
the BDNF Val66Met polymorphism in a group of healthy university students, found that the BDNF 
Val66Met carriers were more susceptible for anxiety symptoms and exhibited an increased cortisol 
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stress response in face of stressful events123. Two further studies also identified an association between 
this polymorphic gene and cases of depression and anxiety. A clinical study found that depressed 
patients with the BDNF Val66 Met polymorphism exhibited higher rates of chronic MDD124. Another 
study found that the BDNF Val66Met polymorphism interacted with early life stress to predict anxiety 
and depression125.  
Most of the evidence gathered in this area does not support a positive association between 
BDNF Val66Met polymorphism and stress-related disorders, particularly MDD and/or PTSD126,127. For 
example a meta-analysis which evaluated the association between BDNF Val66Met polymorphism and 
depressed (MDD) individuals, did not found an association between these two variables126. Another 
meta-analysis which evaluated the same polymorphism with anxiety disorders also did not found an 
association between the variables128. A further meta-analysis did not found an association with 
PTSD127. 
 
Epigenetic Factors in Stress Resilience  
Epigenetics corresponds to the functional alterations in the chromatin structure that trigger long-
lasting modifications in gene expression without creating changes in the DNA sequence129,130. These 
functional alterations help to regulate the phenotype and gene expression of an individual using 
mechanisms such as DNA methylation and histone methylation and acetylation, among others17,18. 
Recent research with monozygotic twin studies have determined that during the lifetime of these 
individuals, there is a meaningful and profound accumulation of epigenetic differences that could be 
explained by distinctive life development events and/or stressful experiences131. In fact, various studies 
have shown that hardship and adversity experienced during youth can result in persistent epigenetic 
marks in the genome that alter gene expression and induce both neural and behavioural changes across 
adulthood132. These epigenetic modifications are known to be implicated in social and maternal 
behaviour, learning and memory deficits, depression and PTSD symptomatology129,130. Recent 
advances in our understanding of the epigenetics of the regulation of stress focuses on at least two 
distinct aspects of stress-induced epigenetic pathology or resilience. This is through mechanisms such 
as DNA methylation or histone methylation, and/or acetylation129,130. Although there has been recent 
progress toward understanding the epigenetic regulation of stress and how such mechanisms contribute 
to susceptibility and resilience to stress-related disorders, careful interpretation is required as this area 
remains largely unexplained129.  
 
- DNA Methylation 
 DNA methylation is a biochemical process known for altering the expression of genes in cells 
when cells divide and differentiate. It is also known to be factor in the neural development of the 
organism and is potentially linked to psychiatric disorders130. A series of studies have already linked 
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the biochemical process of DNA methylation to psychiatric conditions129,130. Post-mortem studies of 
suicide victims with a history of childhood abuse found that increased DNA methylation of a specific 
exon 17 glucocorticoid receptor (NR3C1) gene expression promoter in the hippocampus decreased 
hippocampal GR expression. This in comparison with other postmortem victims of sudden or 
accidental death without history of childhood abuse133. Another human study aimed to compare the 
expression of DNA methyltransferase (DNMT) messenger Ribonucleic Acid (mRNA) between 
individuals who committed suicide and had a MDD diagnosis with individuals who died suddenly as a 
result of other causes other than suicide. The first ones had significant alterations in the DNMT gene 
transcripts expression in brain areas including the frontopolar cortex, amygdala and the paraventricular 
nucleus of the hippocampus134. Thus, this study shown that DNMT-3B expression was augmented in 
areas like the frontopolar cortex, previously known to be linked with an increase in DNA methylation 
of the γ-aminobutyric acid (GABA)(A) receptor alpha-1 subunit promoter region18,134. Additionally, 
another study aimed to evaluate the effect of gene expression and PTSD-associated methylation in 33 
candidate genes. Their findings suggested that higher DNA methylation of Mannosidase Alpha Class 
2C Member 1 (MAN2C1) shown to relate with higher exposure to potentially traumatic situations and 
predictive of PTSD135. Nevertheless, the precise role of MAN2C1 in the stress response remains 
unclear136.   
  
- Histone Methylation and Acetylation 
 Histone Methylation is a biochemical process through which a methyl group is shifted into 
amino acids of histone protein in chromosomes132. As a mechanism, histone methylation is linked with 
stimulation of the neural pathways and potentially for its function in learning and long-term memory137. 
Scientific studies have already showed that female rats have different behavioural patterns of 
interaction with their offspring. While some mother rats exhibit increased levels of nurturing 
behaviours (such as nursing, licking, grooming), others do not138. These different nurturing behaviours 
have a significant impact, where offspring of high-nurturing mothers are known for exhibiting less 
fearfulness, anxiety, reduced corticosterone responses to stress, increased central benzodiazepine 
receptor density in the amygdala and locus coeruleus and higher quantities of glucocorticoid receptors 
(GR) gene promoter in the hippocampus138,139. Interestingly, superior hippocampal GR expressions in 
the offspring are thought to be mediated by the transcription factor Nerve Growth Factor-Inducible 
protein A (NGFI-A)139. For example, in a study where offspring rats received low levels of nurturing 
care from their mothers exhibited an augmented methylation of the GR gene promoter at the NGFI-A 
binding site in the hippocampus139. Thus, lower levels of GR expression in the hippocampus led to 
several traits in adulthood, including higher levels of corticosterone (both before and after stress 
exposure), and higher levels of anxiety-like behaviours. Thus, these differences observed in 
methylation appear the first weeks of life and continue into their adulthood139. 
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 Histone Acetylation is the biochemical process by which the lysine for the histone core is 
acetylated as part of gene regulation140. According to some rodent studies, histone acetylation has been 
observed in several regions of the hippocampus after exposure to acute stress, which could potentially 
lead to its role in memory formation and stress response132. Scientific evidence that histone acetylation 
could have a significant role in depression was found through studies showing that the intracerebral and 
systemic administration of several Histone Deacetylase Inhibitors (HDACi) either alone or combined 
with antidepressants, where results showed, in a variety of animal models, improved antidepressant 
responses132. Another animal study revealed that histone acetylation (H3K14ac) is briefly reduced and 
then augmented in the nucleus accumbens (a central region of the limbic system) after chronic social 
defeat stress, where this action was reflected by a decrease in Histone Deacetylase 2 (HDAC2). 
Supporting this evidence, another study also found similar effects in the nucleus accumbens of 
depressed humans who have been evaluated postmortem141. They highlight that histone acetylation has 
an important function in the development of stress and depression141,142. Additionally, another study 
supported the impact of histone acetylation in animal models by providing evidence that 
overexpression of dominant negative HDAC2 in the nucleus accumbens resulted in antidepressant-like 
behaviours, compared to controls. However, an overexpression of a similar version of the HDAC2 
(strongly related with chromatin) in small rodents was linked with more depression-like behaviours132. 
Though, animal studies with the Histone Deacetylase 5 (HDAC5) suggest a protective effect in the 
nucleus accumbens. For example, a study with small rodents subjected to chronic social defeat stress, 
exhibited a reduction in the HDAC5 expression while chronic antidepressant treatment led to an 
increased HDAC5 expression. Thus, lacking of HDAC5 expression increased depressive-like 
behaviours when compared with controls143. 
 
DEVELOPMENTAL FACTORS AND STRESS RESILIENCE OVER THE LIFE CYCLE 
The accrued scientific evidence also suggests that environmental stress over the life cycle can 
be extremely important in explaining an individual’s risk to a stress-related psychiatric injury, and 
conversely, stress resilience144,145. Human and animal studies suggest that severe stressful experiences 
during early life can negatively affect the development of stress response system and cause long-lasting 
ill-health109,145-147. Strong, frequent and prolonged activation of the stress response system during 
childhood has been labelled toxic stress (e.g. physical/emotional abuse, chronic neglect, constant 
exposure to violence). This can disturb the normal development of the brain and other systems and 
increase the risk of stress-related disorders in adulthood. Thus, the higher number of stressful and/or 
adverse experiences encountered in childhood the higher risk of these individuals to develop cognitive, 
emotional and development problems148. In fact, studies that evaluated parental neglect and abusive 
behaviour toward children during the early weeks of life found fewer stress management skills, lower 
self-independence and higher levels of anxiety and stress. This was reflected in increased HPA Axis 
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and CNS activity when the same individuals were subjected to stressors in later life147. Additionally, 
these early life stressor experiences led to hyper-functioning of NE system, reduction in the 
hippocampal volume, and amygdala responsiveness to negative facial expressions149,150.     
 Research in human and animal models suggest that certain factors can play an exceptionally 
important role in determining whether an early traumatic experience can result in vulnerability or 
resilience to a psychiatric disorder. One of the factors known to play an important role in these 
circumstances is the degree of control that an individual has over the stressor. Another factor is the 
possibility of changing the situation11,18. It is already known that when individuals are led to believe 
that they are unable to change stressful circumstances, “learned helplessness” occurs151. Learned 
helplessness is a mental state where an individual, after experiencing ongoing adverse stimuli 
considered painful or unpleasant, becomes incapable and/or unwilling to avoid consequent encounters 
with the given stimuli. Even if there is the possibility of avoiding it, because they have learnt by 
experience that the stressor cannot be controlled or avoided152. This has been confirmed through a 
classic study involving dogs exposed to erratic shocks151. In studies with animals subjected to shocks 
that could be avoided by behavioural modification, learned helplessness seemed not to occur153. Thus, 
evidence indicates that individuals may learn resilience through experience and hardship, in particular 
by developing qualities that facilitate appropriate coping strategies, adaptation and recovery from 
stress101. Studies also suggest that it may be possible to inoculate individuals against the negative 
effects of exposure to high levels of stress154,155. This concept, termed “stress inoculation”, happens 
when an individual acquires an adaptive stress response to the negative effects of following stressors. 
Stress inoculation is thus seen as a form of immunity against similar stressors which might occur in the 
future, essentially being analogous to vaccine induced immunity against disease156. 
 Particularly animal studies tends to support the stress-inoculation concept and shows that early-
life exposure to stressful events may protect against some of future negative effects of stress100. One 
study evaluated the contribution of early-stressors in the emotional stability of small rodents. The 
researchers randomly exposed a group of infant rats to intermittent foot shocks, sufficient to elicit 
evasive movements, as a stress task, alongside a control group that did not experience shock. When 
they subjected the same two groups of rodents to a new stressful situation, those that had been 
intermittently subjected to stress displayed an enhanced coping response and a lower emotional 
response157,158. 
  
DISCUSSION 
The neural mechanisms that underlie resilience to stress are extremely complex, involving the 
interaction of neurobiological, genetic and epigenetic components, together with the 
environment10,16,17. Whilst genetic factors interact with neurobiological and epigenetic factors thereby 
affecting the biological characteristics and regulation of neurochemical receptors, environmental 
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factors produce epigenetic alterations in individuals, influencing resilience to stress or risk of a 
psychiatric condition16-18. While not part of this review, other factors such as personality, temperament, 
physical fitness and social support also play a pivotal role in resilience. 
 Our growing understanding of resilience leads us to consider how we could establish a resilient 
profile by examining the complexity of interacting factors. We first noted that a significant number of 
neurochemical elements (such as NPY, DHEA, CRH, galanin, ALLO) have been linked to the acute 
stress response and can be associated with resilience to stress10,11,45,94. Each specific pathway and 
neurochemical element conveyed some protection or promoted resilience when facing stress. However, 
none of these neurobiological effects was highly significant as inconsistencies were reported with 
regard to neuro-protective effects. 
 As some researchers have highlighted, the neurobiological concept of resilience cannot be 
regarded as the interaction of a single neurochemical element but rather the interaction of multiple 
neurochemical elements within a complex network of cells in the human brain45,159. In fact, a study that 
evaluated the negative cumulative effects of multiple physiological dysregulations showed that, when 
considering any of the biological markers individually, a decline in health status was not found to have 
any predictive value. Instead, when all markers were considered, they predicted an accentuated 
cognitive decline and a change in cardiovascular activity5,45. If a similar model were applied to stress-
resilient individuals, by combining neurochemistry and its known components to confer protection and 
including high-levels of NPY, galanin, DHEA, ALLO and the low levels of CRH activation, we may 
come closer to identifying a neurobiological profile of stress-resilient individuals45. The same strategy 
may also be observed of genetic and epigenetic traits.  
 Further complication arises in relating neurobiological processes to psychological states under 
the overarching concept of resilience. For example a particular neurochemical may be found to be co-
present with psychological symptoms of stress or resilience however this co-presence may not be 
sufficient to establish direction of causation. Meaning its presence may conceivably be a cause or 
conversely a response to intrusive symptomology. Indeed the relation that holds between the 
neurobiology and psychology of resilience represents a significant obstacle that will need to be 
addressed in future research. 
This review focuses on the underlying neurochemical and physiological processes associated 
with resilience. As such we did not include literature concerning the important psychological factors 
and character traits related to the subject. However, it should be noted that active coping strategies, 
humour, hardiness and extraversion can promote resilience through fostering feelings of mastery, 
commitment and competence as well as the ability to help others through bonding. Importantly, the 
propensity of resilient individuals to express positive emotions, in relation to negative events, enables 
them to control their anxiety and fears101. A significant number of studies have also indicated positive 
social support has an important factor in maintaining physical and psychological wellbeing. These 
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studies found that higher levels of social support are able to reduce and/or attenuate the impact of 
PTSD and/or MDD159,160. Additionally, there is an emerging literature which also suggests that a 
positive social support environment can moderate individual environmental and genetic vulnerabilities 
and increase their resilience161.  
Furthermore, encountering and overcoming stress-inducing situations may have a beneficial 
effect on the life cycle, in particular over one’s perception of control and sense of stress mastery. 
However, as different individuals have different stress thresholds, a stressor that may promote 
resilience in one individual could result in increased vulnerability in another individual. The line 
between learned helplessness and stress inoculation is a fine one because of the variability of 
individuals in their biological, psychological and social competences16. 
Choosing to focus on the neurobiological domain for signs of resilience, entailed a neglecting of 
the psychological and social domains. As we understand them, the neurobiological, genetic, epigenetic 
and environmental signs of resilience are akin to variables162. In better understanding these variables 
and the relation they stand in to each other we will begin to see a more complete picture of the 
neurobiology of resilience emerge. As research continues, facilitated by advancing technology, our 
understanding will continue to deepen. In turn this will enable the creation of more comprehensive 
profile of a stress resilient individual.  
The notion of a stress resilient profile will be of use to those who operate in high stress 
environments. First, in relation to the successful completion of the given task and secondly in relation 
to the individual’s post-task physical and psychological wellbeing. Initial steps in this area have been 
taken in studies investigating members of the US and Belgian Special Forces Units29,163-166. The UK is 
yet to conduct resilience related neurobiological research within its military population, this, despite 
having a tradition of epidemiological research in military mental health167.  
While understanding in the neurobiological domain is advancing, this review has shown that the 
mechanism of resilience in concert with the psychological domain requires further research. For 
example, the concept of stress inoculation, mentioned above, presupposes a psychological or cognitive 
process in understanding and adaption to the life stressor. In this sense resilience is learnt. 
The concept of a neurobiological stress-resilient profile begs the question as to whether one can 
be created by supplementation. Supplementation may conceivably be used prophylactically as an 
inoculation against stress and the prevention or mediation of intrusive symptomatology. Interestingly, a 
number of studies have isolated hormones related to resilience, an example being increased levels of 
DHEA measured in individuals who demonstrated greater physical and psychological performance 
under stress. However a further human study showed DHEA supplementation did not manifest in any 
observable advantage. Whilst neurobiological insights into a resilient profile are being gained the 
creation of one remains at the moment elusive, without recourse to the psychological domain. 
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The benefits of improved neurochemistry on psychological performance through prophylactic 
supplementation is a topic of fascination and one that will continue to be explored. As it is however we 
should remain aware of an example from history which illustrates this area of research also has the 
potential to be mishandled with negative consequence when applied168. The use of prophylactic drugs 
that target the CNS may reduce fatigue and enhance psychological resilience, however it can also 
interfere with the individual's moral judgement and mood168. 
In conclusion, the promotion of resilience and prevention of psychopathology are of 
fundamental concern to the medical community. Moving forward and building on the important 
insights gained from the current research, an interdisciplinary approach combining neurobiological, 
genetic, epigenetic and personality traits, as well community and group interactions, may work to 
facilitate the development of a stress-resilient profile. This in turn would be significant step toward the 
prevention and treatment of stress-related psychiatric conditions such as PTSD or MDD.  
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